---
title: "Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues"
date: "2025-02-11 18:30:47"
summary: "Thicha studio/iStock via Getty Images  This is my first Biohaven (NYSE:BHVN) article. It is a commercial stage pharma with a deep pipeline. I will cite and reference the following:  Biohaven Highlights from the 01/2025, 43rd Annual J.P. Morgan Healthcare Conference (the \""
categories:
  - "seekalpha_articles"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha_articles"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1214446257/image_1214446257.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

![Blue alcohol plastic bottle or anti bacteria to prevent the spread of germs at background, That was It costs expensive price and high priced products concept](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1214446257/image_1214446257.jpg?io=getty-c-w750) 



Thicha studio/iStock via Getty Images





This is my first Biohaven (NYSE:[BHVN](https://seekingalpha.com/symbol/BHVN "Biohaven Ltd.")) article. It is a commercial stage pharma with a deep pipeline.

I will cite and reference the following:

1. Biohaven Highlights from the 01/2025, 43rd Annual J.P. Morgan Healthcare Conference (the "

[seekalpha_articles](https://seekingalpha.com/article/4756973-biohaven-highly-priced-biotech-with-broad-pipeline-but-no-revenues)
